Related Experiment Video
Updated: Feb 12, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer
Wei Feng1, Qianyi Xie1, Suo Liu1
1Departments of Cardiothoracic Surgery, Third Xiangya Hospital of Central South University, Changsha, China.
Abstract:
Gefitinib has been widely used in the first-line treatment of advanced EGFR-mutated non-small-cell lung cancer (NSCLC). However, many NSCLC patients will acquire resistance to gefitinib after 9-14 months of treatment. This study revealed that Krüppel-like factor 4 (KLF4) contributes to the formation of gefitinib resistance in c-Met-overexpressing NSCLC cells. We observed that KLF4 was overexpressed in c-Met-overexpressing NSCLC cells and tissues. Knockdown of KLF4 increased tumorigenic properties in gefitinib-resistant NSCLC cell lines without c-Met overexpression, but it reduced tumorigenic properties and increased gefitinib sensitivity in gefitinib-resistant NSCLC cells with c-Met overexpression, whereas overexpression of KLF4 reduced gefitinib sensitivity in gefitinib-sensitive NSCLC cells. Furthermore, Western blot analysis revealed that KLF4 contributed to the formation of gefitinib resistance in c-Met-overexpressing NSCLC cells by inhibiting the expression of apoptosis-related proteins under gefitinib treatment and activating the c-Met/Akt signaling pathway by decreasing the inhibition of β-catenin on phosphorylation of c-Met to prevent blockade by gefitinib. In summary, this study's results suggest that KLF4 is a promising candidate molecular target for both prevention and therapy of NSCLC with c-Met overexpression.
Insights
Krüppel-like factor 4 (KLF4) drives gefitinib resistance in non-small-cell lung cancer (NSCLC) with c-Met overexpression. Targeting KLF4 may overcome treatment resistance in these NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Gefitinib is a first-line treatment for advanced EGFR-mutated non-small-cell lung cancer (NSCLC).
- Acquired resistance to gefitinib develops in many NSCLC patients within 9-14 months.
- The mechanisms underlying gefitinib resistance, particularly in c-Met-overexpressing NSCLC, require further elucidation.
Purpose of the Study:
- To investigate the role of Krüppel-like factor 4 (KLF4) in the development of gefitinib resistance in NSCLC.
- To explore KLF4's interaction with c-Met signaling in gefitinib-resistant NSCLC cells.
- To assess KLF4 as a potential therapeutic target for overcoming gefitinib resistance in NSCLC.
Main Methods:
- Analysis of KLF4 expression in c-Met-overexpressing NSCLC cells and tissues.
- In vitro studies involving KLF4 knockdown and overexpression in gefitinib-sensitive and resistant NSCLC cell lines.
- Western blot analysis to examine protein expression and signaling pathway activation (c-Met/Akt/β-catenin).
Main Results:
- KLF4 was overexpressed in c-Met-overexpressing NSCLC cells and tissues.
- KLF4 knockdown reduced tumorigenicity and increased gefitinib sensitivity in c-Met-overexpressing resistant NSCLC cells.
- KLF4 overexpression decreased gefitinib sensitivity in sensitive NSCLC cells.
- KLF4 promoted gefitinib resistance by inhibiting apoptosis and activating the c-Met/Akt pathway.
Conclusions:
- KLF4 plays a critical role in mediating gefitinib resistance in NSCLC with c-Met overexpression.
- KLF4 influences gefitinib sensitivity by modulating apoptosis and the c-Met/Akt signaling pathway.
- KLF4 represents a promising molecular target for the prevention and treatment of c-Met-overexpressing NSCLC.
Related Concept Videos
Treatment Resistant Cancers
Transcription Factors
The Eukaryotic Promoter Region
Lung Capacity
Resistivity
Resistance

